Cytokinetics, Inc. (CYTK)
53.08
+1.62
(+3.16%)
USD |
NASDAQ |
Nov 20, 10:00
Cytokinetics Cash from Operations (Quarterly) : -124.02M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -124.02M |
| June 30, 2026 | -159.84M |
| March 31, 2026 | -145.46M |
| December 31, 2025 | -142.65M |
| September 30, 2025 | -107.50M |
| June 30, 2025 | -128.24M |
| March 31, 2025 | -131.62M |
| December 31, 2024 | -65.57M |
| September 30, 2024 | -101.50M |
| June 30, 2024 | -99.31M |
| March 31, 2024 | -129.51M |
| December 31, 2023 | -74.04M |
| September 30, 2023 | -96.20M |
| June 30, 2023 | -121.80M |
| March 31, 2023 | -122.29M |
| December 31, 2022 | -98.19M |
| September 30, 2022 | -81.63M |
| June 30, 2022 | -90.48M |
| March 31, 2022 | -29.22M |
| December 31, 2021 | -44.74M |
| September 30, 2021 | -38.77M |
| June 30, 2021 | -29.50M |
| March 31, 2021 | -29.52M |
| December 31, 2020 | 52.15M |
| September 30, 2020 | 14.37M |
| Date | Value |
|---|---|
| June 30, 2020 | -27.44M |
| March 31, 2020 | -30.14M |
| December 31, 2019 | -19.06M |
| September 30, 2019 | -20.27M |
| June 30, 2019 | -24.68M |
| March 31, 2019 | -26.91M |
| December 31, 2018 | -12.33M |
| September 30, 2018 | -32.24M |
| June 30, 2018 | -26.85M |
| March 31, 2018 | -29.81M |
| December 31, 2017 | -24.07M |
| September 30, 2017 | -25.48M |
| June 30, 2017 | -31.26M |
| March 31, 2017 | -20.94M |
| December 31, 2016 | 77.83M |
| September 30, 2016 | -12.12M |
| June 30, 2016 | -11.22M |
| March 31, 2016 | -17.51M |
| December 31, 2015 | -9.942M |
| September 30, 2015 | -10.35M |
| June 30, 2015 | -9.187M |
| March 31, 2015 | 34.36M |
| December 31, 2014 | -8.13M |
| September 30, 2014 | -9.515M |
| June 30, 2014 | -9.376M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| BridgeBio Pharma, Inc. | -44.17M |
| Alnylam Pharmaceuticals, Inc. | 340.98M |
| Arrowhead Pharmaceuticals, Inc. | -192.40M |
| BioMarin Pharmaceutical, Inc. | 188.21M |
| Exelixis, Inc. | 279.96M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 67.93M |
| Cash from Financing (Quarterly) | 4.80M |
| Free Cash Flow | -588.58M |
| Free Cash Flow Per Share (Quarterly) | -0.897 |
| Free Cash Flow to Equity (Quarterly) | -126.72M |
| Free Cash Flow to Firm (Quarterly) | -86.24M |
| Free Cash Flow Yield | -7.96% |